| Literature DB >> 32296477 |
A Santoso1, T R Yoon2, K S Park2, I B Anwar1, P Utomo1, B Soetjahjo1, T Sibarani1.
Abstract
INTRODUCTION: Periprosthetic joint infection (PJI) of the hip due to methicillin-resistant bacteria is difficult to treat and remain a challenge for arthroplasty surgeon.Entities:
Keywords: hip joint; methicillin-resistant; periprosthetic infection; two-stage revision
Year: 2020 PMID: 32296477 PMCID: PMC7156181 DOI: 10.5704/MOJ.2003.003
Source DB: PubMed Journal: Malays Orthop J ISSN: 1985-2533
Baseline data of Methicillin-resistant group versus control group CRP: C-reactive protein, ESR: erythrocyte sedimentation rate; WBC: white blood count; THA: total hip arthroplasty; I&D: irrigation and debridement; COPD: chronic obstructuve pulmonary disease; HHS: Harris hip score.
| Variable | Methicillin-resistant (Infection group n: 28) | Control (group n: 29) | p-value |
|---|---|---|---|
| Age (years) | 68.9 (range, 49-82) | 65.9 (range, 36-84) | 0.37 |
| Gender | 0.70 | ||
| Male | 15 | 17 | |
| Female | 13 | 12 | |
| Body mass index (kg/m2) | 23.4 (range,19-34) | 23.6 (range, 16-34) | 0.81 |
| CRP (mg/l) | 5.2 (range,0.37-18.1) | 5.9 (range, 0.5-24) | 0.63 |
| ESR (mm/hr) | 68.3 (range 9-116) | 70.5 (range, 11-118) | 0.78 |
| WBC (x103/ml) | 11.6 (range,7.1-19.5) | 13.0 (range,4.2-23.2) | 0.24 |
| Follow-up period (months) | 33.7 (range, 12-67) | 28.4 (range, 12-73) | 0.27 |
| Type of infected hip arthroplasty | 0.01 | ||
| Primary THA | 3 | 18 | |
| Revision THA | 11 | 2 | |
| Bipolar hemiarthroplasty | 14 | 9 | |
| Pre-operative antibiotic treatment | 0.38 | ||
| Yes | 5 | 8 | |
| No | 23 | 21 | |
| History of previous I& | 0.97 | ||
| Yes | 2 | 2 | |
| No | 26 | 27 | |
| Pre-operative HHS | 50.1 (range, 21-71) | 42.1 (range, 11-72) | 0.03 |
| Comorbidities | |||
| Hypertension | 14 | 9 | |
| Diabetes mellitus | 5 | 4 | |
| Cerebrovascular disease | 1 | 1 | |
| Cardiovascular disease | 2 | 3 | |
| Renal insufficiency | 5 | 3 | |
| COPD | 3 | 1 | |
| Liver disease | 2 | 2 | |
| Malignancy | 1 | 2 |
Fig. 1:(a) Infected bipolar right hip hemiarthroplasty in a female 59-year-old due to MRSE. (b) Insertion of antibiotic cement spacer, extended trochanteric osteotomy was needed to remove the infected femoral stem. (c) Revision THA was performed after 54 days interval period. (d) Radiograph of final follow-up at 33 months, patient has excellent clinical outcome with no sign of infection.
Treatment results of two-stage revision of Methicillin-resistant group versus control group
| Treatment Results | Methicillin-resistant group (n:28) | Control group (n:29) | p-value |
|---|---|---|---|
| Interval period between stage (days) | 151.4 (range, 33-616) | 144.2 (range, 28-584) | 0.84 |
| Time to normal CRP (days) | 112.8 (range, 11-601) | 105 (range, 12-575) | 0.83 |
| Received reimplantation | 26 (92.8% | 26 (89.6%) | 0.66 |
| Single time cement spacer | 23 | 24 | |
| ≥times cement spacer | 2 | 1 | |
| Spacer and Girdlestone | 1 | 1 | |
| Never reimplantation | 2 (7.2%) | 3 (10.4%) | |
| Spacer retention | 1 | 3 | |
| Convert to Girdlestone | 1 | 0 | |
| Recurrency of infection | |||
| (after reimplantation) | 6 (23.1%) | 2 (7.6%) | 0.12 |
| I& | 0 | 0 | |
| One-stage revision | 1 | 0 | |
| Two-stage revision | 4 | 2 | |
| Girdlestone | 1 | 0 | |
| Overall infection control rate | 20/28 (71.4%) | 26/29 (89.6%) | 0.08 |
| HHS at final follow-up | 82.2 (range, 47-94) | 83.6 (range, 67-95) | 0.58 |
| ETO during 1st stage | 0.90 | ||
| Yes | 15 | 16 | |
| No | 13 | 13 | |
| Adverse events during spacer period | >0.05 | ||
| Spacer dislocation | 2 | 4 | |
| Periprosthetic fracture | 5 | 6 | |
| Cement dislodgement | 2 | 4 | |
| Adverse events after reimplantation | >0.05 | ||
| Aseptic loosening | 1 | 0 | |
| Dislocation | 2 | 2 | |
| Periprosthetic fracture | 0 | 1 |
CRP: C-reactive protein, I&D: irrigation and debridement; HHS: Harris hip score; ETO: extended trochanteric osteotomy.
List of isolated pathogen in Methicillin-resistant group versus control group
| Isolated pathogen | MR infection | Other infection | Number of reimplantation | Number of recurrency |
|---|---|---|---|---|
| MRSE | 16 | - | 16 | 3 |
| MRSA | 10 | - | 8 | 3 |
| MRCNS | 2 | - | 2 | - |
| MSSA | - | 6 | 6 | - |
| Staphylococcus capitis | - | 3 | 3 | - |
| Streptococcus haemolyticus | - | 1 | 1 | - |
| Proteus mirabilis | - | 1 | 1 | - |
| Pseudomonas aeruginosa | - | 5 | 4 | - |
| Corinobacterium sp. | - | 1 | 1 | - |
| Escherecia coli | - | 1 | 1 | - |
| Streptococcus Sanguinis | - | 1 | 1 | 1 |
| Acinetobacter Baumani | - | 1 | 1 | - |
| Klebsiella Pneumonia | - | 1 | 1 | - |
| Candida Albicans | - | 1 | - | - |
| Mycobacterium sp. | - | 1 | - | - |
| Multiorganism | - | 6 | 6 | 1 |
| MRSA: Methcillin-resistant Staphylococcus | aureus; MRSE: | Methicillin-resistant Staphyl | ococcus epidermidis; | MRCNS: Methicillin- |
MRSA: Methcillin-resistant Staphylococcus aureus; MRSE: Methicillin-resistant Staphylococcus epidermidis; MRCNS: Methicillin-resistant coagulase-negative Staphylococcus; MSSA: Methicillin-sensitive Staphylococcus aureus